Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Voyageur Secures First International Sales Contract worth US$1.9 Million (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Braxia Scientific Corp C.BRAX

Alternate Symbol(s):  BRAXF

Braxia Scientific Corp. is a Canada-based company, which is primarily focused on owning and operating multidisciplinary clinics, providing treatment for mental health disorders, and research activities related to discovering and commercializing drugs and delivery methods. The Company seeks to develop ketamine and derivatives and other psychedelic products from its Internet protocol (IP) development platform. The Company has clinic operations in the Canadian cities of Mississauga, Toronto, Kitchener-Waterloo, Ottawa and Montreal. The Company, through its wholly owned subsidiary, the Canadian Rapid Treatment Center of Excellence Inc., it operates multidisciplinary community-based clinics offering rapid-acting treatments for depression located in Mississauga, Toronto, Ottawa, Kitchener and Montreal. Its subsidiaries include Altmed Capital Corp., Artisan Growers Ltd., KetaMD, Inc., Novo Formulations Ltd. and Tassili Life Sciences Corp.


CSE:BRAX - Post by User

Braxia Scientific Corp > Elephant is coming
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(4)
•••
Comment by TFTheygonnasayon May 14, 2020 12:01pm
120 Views
Post# 31028001

RE:RE:RE:RE:RE:Elephant is coming

RE:RE:RE:RE:RE:Elephant is coming Sure Thankfully psilocybin has been decriminalised in a number of US states Making for some Accessibility and paving the way for Regulatory framework One day…. with the punishment a misdemeanor at this stage.  Sure these ketamine infusion clinics can be described as a market entry point they are so far out from a business of today… I would love to know the annual earnings of that clinic year to date given the outlandish evaluation.  Access to this clinic is still guarded by a gatekeeper AND that gatekeeper is a physician. Call your family GP see how easy this Ketamine script is hahahahahahhahah  have a read buddy “Multidisciplinary input” is required,  Ontario likely has the same guidelines.
https://www.cpsbc.ca/files/pdf/NHMSFAP-AS-Pain-Infusion-Clinic.pdf


<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities